These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33815290)

  • 1. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
    Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
    Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
    Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
    Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol.
    Šprem Goldštajn M; Dumančić S; Mikuš M
    J Obstet Gynaecol Res; 2021 Mar; 47(3):992-1001. PubMed ID: 33372397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
    Velthuis E; Hubbard J; Longobardi S; D'Hooghe T
    Adv Ther; 2020 Dec; 37(12):4831-4847. PubMed ID: 33058045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XM17 Follitropin Alfa (Ovaleap(®)): A Review in Reproductive Endocrine Disorders.
    Hoy SM
    BioDrugs; 2016 Aug; 30(4):379-86. PubMed ID: 27342604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
    Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
    Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
    Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
    J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap
    Winstel R; Wieland J; Gertz B; Mueller A; Allgaier H
    Drugs R D; 2017 Jun; 17(2):305-312. PubMed ID: 28386738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
    Chua SJ; Mol BW; Longobardi S; Orvieto R; Venetis CA; Lispi M; Storr A; D'Hooghe T
    Reprod Biol Endocrinol; 2021 Apr; 19(1):51. PubMed ID: 33794909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
    Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
    Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
    Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
    Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
    Palomba S; Caserta D; Levi-Setti PE; Busnelli A
    J Ovarian Res; 2024 Mar; 17(1):60. PubMed ID: 38486276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.
    Bühler K; Naether OG; Bilger W
    Reprod Biol Endocrinol; 2014 Jan; 12():6. PubMed ID: 24423045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
    Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
    Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study.
    Fisch B; Avrech OM; Pinkas H; Neri A; Rufas O; Ovadia J; Loumaye E
    J Assist Reprod Genet; 1995 Jan; 12(1):26-31. PubMed ID: 7580006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa.
    Olivennes F; Trew G; Borini A; Broekmans F; Arriagada P; Warne DW; Howles CM
    Reprod Biomed Online; 2015 Mar; 30(3):248-57. PubMed ID: 25596910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.